Search
anifrolumab (Saphnelo)
Indications:
- treatment of moderate-to-severe systemic lupus erythematosus
- refractory discoid lupus erythematosus
Adverse effects:
- nasopharyngitis
- upper respiratory tract infections
- bronchitis
- infusion-related reactions
* cytopenias & thrombotic events not observed
Mechanism of action:
- type 1 interferon receptor antagonist
Notes:
- manufacturer AstraZeneca
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
pharmaceutical monoclonal antibody
References
- Walsh N
Thumbs Up From FDA for Anifrolumab in Lupus.
Wonderful news for the lupus community, expert says.
MedPage Today August 2, 2021
https://www.medpagetoday.com/rheumatology/lupus/93856
- Shaw K, Sanchez-Melendez S, Taylor D et al
Assessment of Clinical Response to Anifrolumab in Patients With Refractory
Discoid Lupus Erythematosus.
JAMA Dermatol. Published online March 15, 2023
PMID: 36920401
https://jamanetwork.com/journals/jamadermatology/fullarticle/2802155